BNTC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BN

Mkt Cap

$282.0M

Volume

139.26K

Next Earnings

November 13th

Loading chart

BN

BNTCBenitec Biopharma Inc. Common Stock

BNTC

Pay with—

Available Balance0.00

BN

Mkt Cap

$282.9M

Volume

139.26K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational UpdateBenitec Biopharma announced completion of 12-month follow-up for all six Cohort 1 patients in its BB-301 Phase 1b/2a trial for oculopharyngeal muscular dystrophy (OPMD)-related dysphagia, with clinically meaningful improvements observed. Cohort 2 is fully enrolled with three patients safely treated. The company held a Type C meeting with the FDA regarding pivotal study design and plans to initiate the pivotal trial in mid-2027. Benitec reported $180 million in cash as of June 30, 2026, with operating expenses of $51.2 million for fiscal year 2026.GlobeNewswire Inc. · Sep 14, 2026

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of ResponseBenitec Biopharma announced positive 24-month follow-up results from its BB-301 gene therapy clinical trial for oculopharyngeal muscular dystrophy (OPMD). Patient 1 demonstrated deepening improvements in swallowing function with 60% reduction in post-swallow residue and 78% improvement in dysphagic symptom burden at 24 months. All four patients who completed the 12-month follow-up period met responder criteria, showing durable response to the treatment.GlobeNewswire Inc. · Jan 11, 2026

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational UpdateBenitec Biopharma reported positive Phase 1b/2a trial results for BB-301, a gene therapy targeting Oculopharyngeal Muscular Dystrophy (OPMD), with a 100% responder rate. The FDA granted Fast Track Designation, and the company raised $100 million to advance the therapy's development.GlobeNewswire Inc. · Nov 14, 2025

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular DystrophyBenitec Biopharma will provide an update on its Phase 1b/2a clinical study for BB-301, a gene therapy treatment for Oculopharyngeal Muscular Dystrophy, focusing on results from six patients in Cohort 1.GlobeNewswire Inc. · Nov 3, 2025

Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific ConferenceBenitec Biopharma announced the acceptance of a late-breaking oral abstract for the BB-301 Phase 1b/2a clinical study in Oculopharyngeal Muscular Dystrophy (OPMD) patients. Interim clinical study updates for the first three subjects will be presented at the Muscular Dystrophy Association Clinical and Scientific Conference in March 2025.GlobeNewswire Inc. · Feb 14, 2025

RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034The global RNA-based therapeutic market is expected to grow from $9.46 billion in 2025 to $40.81 billion by 2034, driven by the rising prevalence of genetic disorders and the demand for personalized medicine. North America and Asia Pacific are the key regional markets.GlobeNewswire Inc. · Feb 10, 2025

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle SocietyBenitec Biopharma reported positive data from two subjects treated with low-dose BB-301 in a Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD). The subjects experienced durable, clinically meaningful improvements in swallowing, with one subject achieving a clinically normal swallowing profile.GlobeNewswire Inc. · Oct 12, 2024

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational UpdateBenitec Biopharma reported positive 90-day and 180-day interim clinical data for the first subject dosed with the low-dose of BB-301 in the Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD). The company also dosed a second subject and expects to dose a third subject in Q4 2024. Benitec closed a $40 million private placement financing, extending its cash runway through 2025.GlobeNewswire Inc. · Sep 26, 2024

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle SocietyBenitec Biopharma announced that a late-breaking abstract on its BB-301 gene therapy for oculopharyngeal muscular dystrophy (OPMD) has been accepted for oral presentation at the 29th Annual Congress of the World Muscle Society.GlobeNewswire Inc. · Sep 18, 2024

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phas - GlobeNewswireBenitec Biopharma reports continued improvements in swallowing function for the first subject treated with low-dose BB-301 in its OPMD Phase 1b/2a study, as measured by radiographic assessments and subject-reported outcomes at the 180-day timepoint.GlobeNewswire Inc. · Jul 15, 2024

to start trading

BN

BNTCBenitec Biopharma Inc. Common Stock

BNTC

Pay with—

Available Balance0.00

Your PositionYou don't own any BNTC yet.

Related Tickers

Earnings